Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups.

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.

At Sanofi and Regeneron, it’s all about the kids—at least with respect to their recent advancements of anti-inflammatory powerhouse Dupixent. On Thursday, the FDA signed off on the IL-4 receptor alpha antagonist to treat children between the ages of 1 and 11 who weigh at least 33 pounds with eosinophilic esophagitis (EoE). Dupixent becomes the first treatment in the U.S. for children in this age group with the disorder.

Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities.